WeWorkForHealth CT

We Work for Health CT promotes the economic value of #innovation and #research in the #bioscience sector in Connecticut to our policymakers

[Greater New Haven Chamber of Commerce @GNHCC]

Congratulations to @ArvinasInc who will be honored with the Bioscience Company award at our 22nd Annual Health Care & Life Sciences Awards, presented by @ynhhealth

Wednesday, July 24th at 3:30pm
Canal Dock Boathouse

Register now to attend: https://t.co/sUr0WZDqpY

[WeWorkForHealth CT @WWFHCT]

OP-ED: The Inflation Reduction Act is not what it was promised to be for seniors
#IRA #PartD #biopharma
https://t.co/b5UlSo1227

[PhRMA @PhRMA]

This Friday, March 29, join @GSKUS and other leaders in health care for a @statnews discussion about how we can ensure the patient voice is included in conversations about the significant medical breakthroughs of today. Register for the virtual event: https://t.co/c2QrAAJk0n

[PhRMA @PhRMA]

More transparency on the PBM industry is important, but not enough. Even as the FTC, state AGs, federal and state lawmakers look under the hood of the broken PBM model, the big #PBMs are finding new ways to drive out competition and drive up costs.

[We Work For Health @weworkforhealth]

The EPIC Act is simple: It eliminates the #IRA "pill penalty" so the government doesn't pick winners and losers among different categories of medicine. Read more here: https://t.co/vIqUqRRRVK

[CBIA @CBIANews]

During #RareDiseaseDay, @CTBio noted the diagnostic odyssey for patients can take 7 years, but whole genome sequencing can cut that to weeks or days. “It helps patients and families unbelievably, but it also saves the healthcare system a huge amount of money,” Pescatello says.

[We Work For Health @weworkforhealth]

Don't miss out! Tomorrow, @ITIFdc will hold an expert briefing on Capitol Hill to share its new report on policy threats to America's global leadership in the biopharmaceutical industry.

Learn more and register here: https://t.co/DK8X8XfS23

[PhRMA @PhRMA]

This #AmericanHeartMonth, neurology and emergency room nurse @sharonlamberton shares her experience advocating for new cardiovascular treatments and why it's important that the U.S. policy environment support access to these medicines. https://t.co/M9lJXdlKq0

[Lupus Foundation NE @LupusNE]

#MA patients rely on public-private sector collaboration to bring much-needed medications, including new treatments for #lupus, to the #Rx counter. @POTUS's use of #MarchInRights —which threatens to seize drug patents—will deter this partnership that delivers innovative cures.

[WWFHTX @WWFHTX]

If a White House proposal to seize patents prevails, it will be a “disaster” for American workers and consumers. Learn more. #MarchInRights #BayhDole @weworkforhealth https://t.co/CtiTG1zVPE From @IBTimes

[Biotechnology Innovation Organization @IAmBiotech]

Our CEO Rachel King's op-ed exposes the danger of short-sighted U.S. policies, risking future medical breakthroughs. Government interference threatens life-changing drugs. Stay informed on #biotech innovation impact and preserve the progress made thus far. 💊🔬✨ @RachelKingBio https://t.co/IBDypOqUAm

[PhRMA @PhRMA]

71 novel treatments & vaccines were approved in the U.S. last year to help tackle a variety of diseases and conditions, including:

➡️Alzheimer’s
➡️RSV
➡️Postpartum depression
➡️Sickle Cell Disease
➡️Cancer
➡️ALS
➡️Genetic diseases, like hemophilia A
https://t.co/7TzIkmQk8Y

[WWFHTX @WWFHTX]

.@WWFHCT Chair explains why the #IRA’s so-called drug price “negotiation” is anything but. Instead, it’s a take-it-or-leave-it form of gov’t #pricecontrols, which don’t work. https://t.co/esn9RfVNYL

[Wall Street Journal Opinion @WSJopinion]

President Biden announced the first 10 drugs for price controls, and he’s exaggerating the benefits while ignoring the larger damage.
https://t.co/3Hk2MXU7PU

[PhRMA @PhRMA]

PBMs can steer you toward pharmacies that make them more money. How is that possible? Because they own pharmacies, too. See how these middlemen are putting profits before your health: https://t.co/9fTvQnlzGx

[WeWorkForHealth CT @WWFHCT]

Newsflash: the #IRA’s drug price controls will threaten critical research into the cures and treatments that CT patients living with chronic or rare diseases hope for. @CMSGov’s initial #IRA
drug list is not worth celebrating.

[WeWorkForHealth CT @WWFHCT]

https://t.co/GTUyX8MgEG

[PhRMA @PhRMA]

Soon, the government will release the first list of medicines for price setting, focusing on short-term political objectives vs. the real-world needs of patients — and in the process, ignore existing savings from private sector negotiation & competition: https://t.co/XsBdeK7lZr

[WeWorkForHealth CT @WWFHCT]

Government #PriceSetting for RX drugs is not the answer. We need lawmakers to advocate for policies that support a strong biotechnology industry & result in impactful cost savings for CT patients. Policies that incentivize robust pharmaceutical research & improve patient access.

[WeWorkForHealth CT @WWFHCT]

Research and investment is a huge part of CT's growing bioscience economy- CT has over 45,000 residents employed in an industry-supported job. We cannot let policies like the IRA price setting mechanisms set us back in developing CT's bio industry.

[Biotechnology Innovation Organization @IAmBiotech]

BIO Statement on CMS Announcement of First 10 Drugs Subject to Price Controls Under IRA:
https://t.co/V5dXStPChw

[WeWorkForHealth CT @WWFHCT]

https://t.co/4y7ptIU4QV

[We Work For Health @weworkforhealth]

Gov't-mandated price setting in Medicare is not the solution patients need. #ICYMI, data from WWFH & @VitalTransform illustrates the impact of such policies – hundreds of medicines never created, thousands of jobs lost across the economy. Read the report: https://t.co/mmg0mqNs2x